Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine

References

• LanzaGAFoxKCreaFHeart rate: A risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowingAdv Cardiol200643116
   PubMedGoogle Scholar
• LurjeLWennerblomBTygesenHKarlssonTHjalmarsonAHeart rate variability after acute myocardial infarction in patients treated with atenolol and metoprololInt J Cardiol19976021571649226286
   PubMed Web of Science ®Google Scholar
• LonnEGrewalJDrug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directionsCurr Vasc Pharmacol200643253268
   PubMedGoogle Scholar
• PoulterNRDobsonJESeverPSDahlofBWedelHCampbellNRBaseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo – Scandinavian Cardiac Outcomes Trial)J Am Coll Cardiol2009541311541161
   PubMed Web of Science ®Google Scholar
• FrishmanWHA historical perspective on the development of β-adrenergic blockersJ Clin Hypertens200794 Suppl 31927
   PubMedGoogle Scholar
• EganBMBasileJChiltonRJCohenJDCardioprotection: The role of beta-blocker therapyJ Clin Hypertens (Greenwich)200577409416
   PubMedGoogle Scholar
• Lopez-SendonJSwedbergKMcMurrayJExpert consensus document on beta-adrenergic receptor blockersEur Heart J2004251513411362
   PubMed Web of Science ®Google Scholar
• BakrisGLHartPRitzEBeta blockers in the management of chronic kidney diseaseKidney Int200670111905191317021610
   PubMed Web of Science ®Google Scholar
• MesserliFHGrossmanEBeta-blockers in hypertension: Is carvedilol different?Am J Cardiol2004939A7B12B
   PubMed Web of Science ®Google Scholar
• BrocqMLLeslieSJMillikenPMegsonILEndothelial dysfunction: From molecular mechanisms to measurement, clinical implications, and therapeutic opportunitiesAntioxid Redox Signal200810916311674
   PubMed Web of Science ®Google Scholar
• KrumHSympathetic activation and the role of beta-blockers in chronic heart failureAust N Z J Med1999293418427
   PubMedGoogle Scholar
• ManciaGGrassiGGiannattasioCSeravalleGSympathetic activation in the pathogenesis of hypertension and progression of organ damageHypertension1999344 Pt 272472810523349
   PubMed Web of Science ®Google Scholar
• De JongMJRandallDCHeart rate variability analysis in the assessment of autonomic function in heart failureJ Cardiovasc Nurs2005203186195quiz 196–19715870589
   PubMedGoogle Scholar
• FeldmanDSEltonTSSunBMartinMMZioloMTMechanisms of disease: Detrimental adrenergic signaling in acute decompensated heart failureNat Clin Pract Cardiovasc Med200854208218
   PubMedGoogle Scholar
• FoxKBorerJSCammAJResting heart rate in cardiovascular diseaseJ Am Coll Cardiol2007509823830
   PubMed Web of Science ®Google Scholar
• DiazABourassaMGGuertinMCTardifJCLong-term prognostic value of resting heart rate in patients with suspected or proven coronary artery diseaseEur Heart J2005261096797415774493
   PubMed Web of Science ®Google Scholar
• JouvenXEmpanaJPSchwartzPJDesnosMCourbonDDucimetierePHeart-rate profile during exercise as a predictor of sudden deathN Engl J Med2005352191951195815888695
   PubMed Web of Science ®Google Scholar
• LeeKLWoodliefLHTopolEJPredictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I InvestigatorsCirculation199591616591668
   PubMed Web of Science ®Google Scholar
• KannelWBRisk stratification in hypertension: New insights from the Framingham StudyAm J Hypertens2000131 Pt 23S10S
   PubMed Web of Science ®Google Scholar
• WilhelmsenLBerglundGElmfeldtDThe multifactor primary prevention trial in Goteborg, SwedenEur Heart J198674279288
   PubMed Web of Science ®Google Scholar
• DyerARPerskyVStamlerJHeart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studiesAm J Epidemiol19801126736749
   PubMed Web of Science ®Google Scholar
• GillumRFMakucDMFeldmanJJPulse rate, coronary heart disease, and death: The NHANES I Epidemiologic Follow-up StudyAm Heart J19911211 Pt 1172177
   PubMed Web of Science ®Google Scholar
• GoldbergRJLarsonMLevyDFactors associated with survival to 75 years of age in middle-aged men and women. The Framingham StudyArch Intern Med19961565505509
   PubMedGoogle Scholar
• KannelWBWilsonPBlairSNEpidemiological assessment of the role of physical activity and fitness in development of cardiovascular diseaseAm Heart J19851094876885
   PubMed Web of Science ®Google Scholar
• SinghBNMorbidity and mortality in cardiovascular disorders: Impact of reduced heart rateJ Cardiovasc Pharmacol Ther20016431333111907634
   PubMedGoogle Scholar
• KovarDCannonCPBentleyJHCharlesworthARogersWJDoes initial and delayed heart rate predict mortality in patients with acute coronary syndromes?Clin Cardiol20042728086
   PubMed Web of Science ®Google Scholar
• EagleKALimMJDabbousOHA validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registryJAMA20042912227272733
   PubMed Web of Science ®Google Scholar
• MarchioliRAvanziniFBarziFAssessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chartEur Heart J200122222085210311686666
   PubMed Web of Science ®Google Scholar
• MorrowDAAntmanEMCharlesworthATIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudyCirculation20001021720312037
   PubMed Web of Science ®Google Scholar
• ThomsenTFDavidsenMIbsenHJorgensenTJensenGBorch-JohnsenKA new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials: PRE-CARD and the Copenhagen Risk ScoreJ Cardiovasc Risk200185291297
   PubMedGoogle Scholar
• ConroyRMPyoralaKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE projectEur Heart J20032411987100312788299
   PubMed Web of Science ®Google Scholar
• ChattipakornNIncharoenTKanlopNChattipakornSHeart rate variability in myocardial infarction and heart failureInt J Cardiol2007120328929617349699
   PubMed Web of Science ®Google Scholar
• Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and ElectrophysiologyCirculation1996935104310658598068
   PubMed Web of Science ®Google Scholar
• ReilJCBohmMThe role of heart rate in the development of cardiovascular diseaseClin Res Cardiol2007969585592
   PubMed Web of Science ®Google Scholar
• YoungJBSudden cardiac death syndrome and pump dysfunction: The linkJ Heart Lung Transplant200019Suppl 8S27S31
   PubMed Web of Science ®Google Scholar
• NesslerJNesslerBKitlinskiMSudden cardiac death risk factors in patients with heart failure treated with carvedilolKardiol Pol2007651214171422discussion 1423–142418181053
   PubMed Web of Science ®Google Scholar
• KjekshusJGullestadLHeart rate as a therapeutic target in heart failureEur Heart J Suppl19991Suppl HH64H69
   Web of Science ®Google Scholar
• FlanneryGGehrig-MillsRBillahBKrumHAnalysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockersAm J Cardiol2008101686586918328855
   PubMed Web of Science ®Google Scholar
• HuangRLListermanJGoringJGiesbergCNadingMAButlerJBeta-blocker therapy for heart failure: Should the therapeutic target be dose or heart rate reduction?Congest Heart Fail200612420610quiz 211–212
   PubMedGoogle Scholar
• LechatPEscolanoSGolmardJLPrognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS)Circulation1997967219722059337190
   PubMed Web of Science ®Google Scholar
• LechatPHulotJSEscolanoSHeart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II TrialCirculation2001103101428143311245648
   PubMed Web of Science ®Google Scholar
• DargieHJEffect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trialLancet2001357926613851390
   PubMed Web of Science ®Google Scholar
• PackerMCoatsAJFowlerMBEffect of carvedilol on survival in severe chronic heart failureN Engl J Med2001344221651165811386263
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)Lancet1999353916920012007
   PubMed Web of Science ®Google Scholar
• Poole-WilsonPASwedbergKClelandJGComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trialLancet2003362937771312853193
   PubMed Web of Science ®Google Scholar
• FeldmanDSCarnesCAAbrahamWTBristowMRMechanisms of disease: Beta-adrenergic receptors – alterations in signal transduction and pharmacogenomics in heart failureNat Clin Pract Cardiovasc Med200529475483
   PubMedGoogle Scholar
• Veteran’s Health Administration Pharmacy Benefits Management Services and the Medical Advisory PanelNational PBM drug monograph: Nebivolol (Bystolic)20086 www.pbm.va.gov/monograph/Nebivolol.doc. Accessed Feb 18, 2009
   Google Scholar
• Agabiti RoseiERizzoniDMetabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristicsDrugs200767810971107
   PubMed Web of Science ®Google Scholar
• SimonGJohnsonMLComparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertensionClin Exp Hypertens19931535015098098243
   PubMed Web of Science ®Google Scholar
• KampOSieswerdaGTVisserCAComparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertensionAm J Cardiol2003923344348
   PubMed Web of Science ®Google Scholar
• StoschitzkyKStoschitzkyGBrusseeHBonelliCDobnigHComparing beta-blocking effects of bisoprolol, carvedilol and nebivololCardiology20061064199206
   PubMed Web of Science ®Google Scholar
• PatrianakosAPParthenakisFIMavrakisHEDiakakisGFChlouverakisGIVardasPEComparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month studyAm Heart J20051505985
   PubMed Web of Science ®Google Scholar
• NesslerJNesslerBKitlinskiMGackowskiAPiwowarskaWStepniewskiMConcentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilolKardiol Pol2008662144151discussion 152–15318344152
   PubMed Web of Science ®Google Scholar
• OlssonLGSwedbergKClarkALWitteKKClelandJGSix minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: A systematic reviewEur Heart J2005268778793
   PubMed Web of Science ®Google Scholar
• JafriSMThe effects of beta blockers on morbidity and mortality in heart failureHeart Fail Rev200492115121
   PubMed Web of Science ®Google Scholar
• ShibataMCFlatherMDWangDSystematic review of the impact of beta blockers on mortality and hospital admissions in heart failureEur J Heart Fail20013335135711378007
   PubMed Web of Science ®Google Scholar
• KitzmanDWExercise intoleranceProg Cardiovasc Dis2005476367379
   PubMed Web of Science ®Google Scholar
• JordeUPVittorioTJKasperMEChronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: Time to pace?Eur J Heart Fail200810196101
   PubMed Web of Science ®Google Scholar
• LauerMSLarsonMGEvansJCLevyDAssociation of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart StudyAm Heart J1999137590390910220640
   PubMed Web of Science ®Google Scholar
• LauerMSOkinPMLarsonMGEvansJCLevyDImpaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart StudyCirculation1996938152015268608620
   PubMed Web of Science ®Google Scholar
• WitteKKClarkALChronotropic incompetence in heart failureJ Am Coll Cardiol2006483595author reply 595–596
   PubMed Web of Science ®Google Scholar
• KhanMNPothierCELauerMSChronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol)Am J Cardiol20059691328133316253608
   PubMed Web of Science ®Google Scholar
• MyersJTanSYAbellaJAletiVFroelicherVFComparison of the chronotropic response to exercise and heart rate recovery in predicting cardiovascular mortalityEur J Cardiovasc Prev Rehabil2007142215221
   PubMedGoogle Scholar
• WeissRNebivolol: A novel beta-blocker with nitric oxide-induced vasodilatationVasc Health Risk Manag200623303308
   PubMedGoogle Scholar
• CarvalhoVORodrigues AlvesRXBocchiEAGuimaraesGVHeart rate dynamic during an exercise test in heart failure patients with different sensibilities of the carvedilol therapy Heart rate dynamic during exercise testInt J Cardiol2009118[Epub ahead of print]
   Web of Science ®Google Scholar
• VittorioTJZoltyRKasperMEDifferential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failureJ Cardiovasc Pharmacol Ther20081315157
   PubMed Web of Science ®Google Scholar
• SteckerECFendrickAMKnightBPAaronsonKDProphylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardiaAm Heart J20061514820828
   PubMed Web of Science ®Google Scholar
• HeidlandUEStrauerBELeft ventricular muscle mass and elevated heart rate are associated with coronary plaque disruptionCirculation20011041314771482
   PubMed Web of Science ®Google Scholar
• HjalmarsonAGilpinEAKjekshusJInfluence of heart rate on mortality after acute myocardial infarctionAm J Cardiol19906595475531968702
   PubMed Web of Science ®Google Scholar
• AbildstromSZJensenBTAgnerEHeart rate versus heart rate variability in risk prediction after myocardial infarctionJ Cardiovasc Electrophysiol2003142168173
   PubMed Web of Science ®Google Scholar
• SteinPKDomitrovichPPHuikuriHVKleigerRETraditional and nonlinear heart rate variability are each independently associated with mortality after myocardial infarctionJ Cardiovasc Electrophysiol20051611320
   PubMed Web of Science ®Google Scholar
• ZuanettiGHernndes-BernalFRossiAComerioGPaolucciGMaggioniAPRelevance of heart rate as a prognostic factor in myocardial infarction: The GISSI experienceEur Heart J Suppl19991Suppl HH52H57
   Web of Science ®Google Scholar
• KjekshusJKImportance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trialsAm J Cardiol1986571243F49F
   PubMed Web of Science ®Google Scholar
• GundersenTGrottumPPedersenTKjekshusJKEffect of timolol on mortality and reinfarction after acute myocardial infarction: Prognostic importance of heart rate at restAm J Cardiol19865812024
   PubMed Web of Science ®Google Scholar
• TuiningaYSCrijnsHJBrouwerJEvaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patientsCirculation19959212341534238521562
   PubMed Web of Science ®Google Scholar
• LampertRIckovicsJRViscoliCJHorwitzRILeeFAEffects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack TrialAm J Cardiol2003912137142
   PubMed Web of Science ®Google Scholar
• BasuSSeniorRRavalUvan der DoesRBrucknerTLahiriABeneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trialCirculation1997961183191
   PubMed Web of Science ®Google Scholar
• LouisWJMcNeilJJDrummerOHPharmacology of combined alpha-beta-blockade. IDrugs198428Suppl 21634
   PubMedGoogle Scholar
• PedersenMECockcroftJRThe vasodilatory beta-blockersCurr Hypertens Rep200794269277
   PubMed Web of Science ®Google Scholar
• MacCarthyEPBloomfieldSSLabetalol: A review of its pharmacology, pharmacokinetics, clinical uses and adverse effectsPharmacotherapy1983341932196310529
   PubMed Web of Science ®Google Scholar
• VermaSPSilkeBHussainMSympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipineJ Hypertens1988611897904
   PubMed Web of Science ®Google Scholar
• StoleruLWijnsWvan EyllCBouvyTVan NuetenLPouleurHEffects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: Comparison with D-L-nebivolol and atenololJ Cardiovasc Pharmacol1993222183190
   PubMed Web of Science ®Google Scholar
• PalatiniPGranieroGRMorminoPRelation between physical training and ambulatory blood pressure in stage I hypertensive subjects. Results of the HARVEST Trial. Hypertension and Ambulatory Recording Venetia StudyCirculation199490628702876
   PubMedGoogle Scholar
• BohmMReilJCDanchinNThoenesMBramlagePVolpeMAssociation of heart rate with microalbuminuria in cardiovascular risk patients: Data from I-SEARCHJ Hypertens2008261182518090536
   PubMed Web of Science ®Google Scholar
• MadsenLBRasmussenJKMollerDSNyvadOPedersenEBHeart rate variability in white-coat hypertensionBlood Press Monit20081326571
   PubMed Web of Science ®Google Scholar
• GillmanMWKannelWBBelangerAD’AgostinoRBInfluence of heart rate on mortality among persons with hypertension: The Framingham StudyAm Heart J1993125411481154
   PubMed Web of Science ®Google Scholar
• LevyBImportance of improving tissue perfusion during treatment of hypertensionJ Hypertens Suppl2006245S6S9
   PubMedGoogle Scholar
• LevyBI[The importance of microcirculation and tissue perfusion in hypertension]Curr Med Res Opin200521Suppl 5S1S6
   PubMedGoogle Scholar
• CampeloMPoloniaJSerraoPCerqueira-GomesMEvaluation of the sympathetic nervous system using heart rate variability and plasma hormones in hypertensive patients treated with cilazapril and atenololCardiology1996875402408
   PubMed Web of Science ®Google Scholar
• ChernCMHsuHYHuHHChenYYHsuLCChaoACEffects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertensionJ Cardiovasc Pharmacol2006472169174
   PubMed Web of Science ®Google Scholar
• Lund-JohansenPHemodynamic consequences of long-term beta-blocker therapy: A 5-year follow-up study of atenololJ Cardiovasc Pharmacol197915487495
   PubMed Web of Science ®Google Scholar
• BangaloreSParkarSGrossmanEMesserliFHA meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitusAm J Cardiol200710081254126217920367
   PubMed Web of Science ®Google Scholar
• BradleyHAWiysongeCSVolminkJAMayosiBMOpieLHHow strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysisJ Hypertens200624112131214117053529
   PubMed Web of Science ®Google Scholar
• CruickshankJMAre we misunderstanding beta-blockersInt J Cardiol200712011027
   PubMed Web of Science ®Google Scholar
• SarafidisPABakrisGLDo the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?J Clin Hypertens (Greenwich)200685351356quiz 357–35816687944
   PubMedGoogle Scholar
• StafylasPCSarafidisPACarvedilol in hypertension treatmentVasc Health Risk Manag200841233018629377
   PubMedGoogle Scholar
• WeberMABakrisGLTarkaEAIyengarMFleckRSicaDAEfficacy of a once-daily formulation of carvedilol for the treatment of hypertensionJ Clin Hypertens (Greenwich)2006812840849
   PubMedGoogle Scholar
• BakrisGLFonsecaVKatholiREMetabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trialJAMA2004292182227223615536109
   PubMed Web of Science ®Google Scholar
• von FalloisJFaulhaberHD[Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study]Fortschr Med Orig2000118Suppl 2778215700490
   PubMedGoogle Scholar
• MunzelTGoriTNebivolol: The somewhat-different beta-adrenergic receptor blockerJ Am Coll Cardiol2009541614911499
   PubMed Web of Science ®Google Scholar
• SchmidtACFlickBJahnEBramlagePEffects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteersVasc Health Risk Manag20084490991519066009
   PubMedGoogle Scholar
• BangaloreSSawhneySMesserliFHRelation of beta-blocker-induced heart rate lowering and cardioprotection in hypertensionJ Am Coll Cardiol2008521814821489
   PubMed Web of Science ®Google Scholar